Harvard Business Review

JULY 23, 2015

For years, there has been a push within the pharmaceutical industry to move “beyond the pill” — in other words, to build and deploy complementary services and solutions to diversify revenue sources. However talented they might be, these individuals often lack experience building non-pharma service businesses.

Pharmaceuticals 8

Pharmaceuticals Health Care Industry Committee 8

Harvard Business Review

OCTOBER 23, 2014

The new business model has yet to solidify, and the leaders have yet to emerge. That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. They are collaborating with (sometimes highly unlikely) partners. They’re also sharing risk.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

DECEMBER 20, 2011

Although the two stories could not appear to differ more, both offer business leaders strategic lessons that are intriguingly similar. The Lipitor story seems to be about a managed end: the highly anticipated demise (due to the expiration of its patent last Nov. 30) of a blockbuster prescription drug. Both Pfizer and.

Disintermediation 14

Disintermediation Industry Pharmaceuticals Price 14

Harvard Business Review

JUNE 22, 2016

Different industries and different business models have always maintained different percentages of these asset types. Digital transformation requires that companies reallocate their asset portfolio to support new, digitally enabled business models. These assets are typically overlooked, undervalued, and under-managed.

Intangible Assets 8

Intangible Assets Business Model How To Intellectual Capital 8

Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. Accordingly, I transformed the business model ? from that of a fully integrated pharmaceutical company into a company that retained key technical expertise (e.g.,

Company 8

Company Pharmaceuticals Biotechnology Short-term 8

Harvard Business Review

AUGUST 14, 2018

“Death by a Thousand Cuts” Based on a comprehensive five-year study, my new research paper, published in the Academy of Management Discoveries this year, systematically identifies the reasons behind the failures of major Western digital firms in China. poor management of relations with Chinese regulators and the government.

Competitive Advantage 9

Competitive Advantage Business Model Technology Marketing 9

Harvard Business Review

JUNE 14, 2017

Their business models are at serious risk of failure in the next three to five years. Some firms have managed it, in healthcare and in other arenas — think of QuintilesIMS as a source of pharmaceutical sales data, Nielsen as the authority on TV viewer habits, and the U.S. What’s a data provider to do?

Health Care 8

Health Care Levitt Competitive Advantage Pharmaceuticals 8

Harvard Business Review

NOVEMBER 8, 2017

The rising flood of hardware, pharmaceuticals, and technical expertise from American manufacturers and hospital companies, which is connected to the needs of a growing number of hospitals, is also pushing many systems closer to the U.S. Over the same period, pharmaceutical exports have doubled. Insight Center. Transforming Health Care.

Health Care 8

Health Care Tourism Pharmaceuticals Cost 8

Harvard Business Review

OCTOBER 29, 2012

The nay-sayers, on the other hand, can cite the passionately defended view of the pharmaceutical industry that the cost of discovering innovative disease-curing molecules has been rising crazily — the basis for perennial campaigns for stronger intellectual property rights to safeguard pharma investments.

Cost 8

Cost Innovation Wireless Disruptive Innovation 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

JANUARY 27, 2016

And use a business model with structural cost advantages (relative to existing solutions). The reason these characteristics of disruption are important are that when all three are present, it’s difficult for an existing business to respond to competition. Is 23andMe potentially disruptive to pharmaceutical companies?

Disruptive Innovation 8

Disruptive Innovation Innovation Short-term Long-term 8

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. It could upend supply chains, business models, customer relationships, and even entrepreneurship itself. 3D printing is poised to redefine global manufacturing and distribution.

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

FEBRUARY 17, 2011

Nadathur's portfolio includes firms operating in drug discovery research, companion diagnostics, pharmaceutical analytics, reimbursement claims processing, patient relationship management, and specialty healthcare delivery for running clinical trials — and they all work together.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15

Harvard Business Review

JUNE 3, 2016

We know that when IT projects fail, it is usually not because the technology didn’t work (although this can sometimes be the case), but because the changes required at an organizational and employee level weren’t managed effectively. They often have to be made before the new digital system is introduced. In a major U.K.

Tools 8

Tools Supply Chain CRM Technology 8

Harvard Business Review

OCTOBER 22, 2013

The business game is changing due to convergence — a process by which the boundaries across industries, businesses, markets, geographies, and/or customer experiences become blurred, resulting in new business opportunities for serving customer needs and improving customer value. Pivots don’t occur overnight; they can be seen.

Skills 8

Skills Power Six Sigma Disruptive Innovation 8

Harvard Business Review

DECEMBER 5, 2016

They are empowered by – and in frequent communication with – senior management. Japanese pharmaceutical Eisai used them to improve care for Alzheimer’s patients. Japanese pharmaceutical Eisai used them to improve care for Alzheimer’s patients. in less than five years. Shared Spaces.

Library 8

Library Strategy Reference Bottom-up 8

Harvard Business Review

SEPTEMBER 20, 2013

For example, a product evaluating nonprofit organizations may be highly useful to a wealth manager seeking to help his client to select a charity as part of a value-added tax efficiency service. Execution Knowledge management'

Execution 8

Execution Metrics Content Christensen 8

Harvard Business Review

APRIL 22, 2013

Most of us think of biotech as the province of multinational pharmaceutical corporations and well-funded ventures, but the founders of BioCurious believe (as they say in their mission statement) "that innovations in biology should be accessible, affordable, and open to everyone." Socialize your underused assets.

Mission Statement 8

Mission Statement Class Learning-by-Doing Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 7, 2015

They allow managers to suspend normal rules in an acceptable way and they provide an effective audiovisual medium for absorbing ideas. People Express, for example, is a business simulator that provides players with a rich inside perspective on starting and managing an airline.

Seminar 8

Seminar Learning Curve Strategy Comparison 8

Harvard Business Review

SEPTEMBER 5, 2016

Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. recently announced that its members are committing to transform 75% of their contracts into pay-for-performance models by 2020. ” Health care.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

AUGUST 17, 2015

It could be an ideal location for healthcare organizations, but also for those in applied sciences, biotechnology, and pharmaceuticals. And secondly, the business model for Cuban biotechnology has been laughably bad. pharmaceutical company could be a great asset in the future. We know two things about biotech in Cuba.

Biotechnology 8

Biotechnology Tourism Human Capital Pharmaceuticals 8

Harvard Business Review

FEBRUARY 4, 2013

Perhaps surprisingly, two leading examples come from pharmaceutical companies. We're moving towards innovation in technology, pricing, business models and partnerships," explains head of corporate responsibility management, Dorje Mundle, of the company's base-of-the-pyramid operations.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

OCTOBER 28, 2013

You don’t want to run to your manager every time you want something to change,” Dillon says. Ten years into her career there, in the mid-1990s, she realized that the agency’s business model was lacking a digital strategy. “I It’s not essential to have your boss on board — but it can be helpful. Principles to Remember.

How To 10

How To Case Study Politics Reputation 10

Strategy Driven

JANUARY 24, 2011

Closing the Execution Gap : How Great Leaders and Their Companies Get Results by Richard Lepsinger If an organization can’t execute its plans and initiatives, nothing else matters: not the most solid, well thought-out strategy, not the most innovative business model, not even technological breakthroughs that could transform an industry.

Execution 78

Execution Company 360-Degree Feedback Cooper 78

Harvard Business Review

SEPTEMBER 4, 2015

We’ve found that CEOs of big pharmaceutical companies, for example, are more likely to have a background as company lawyers, salespeople, or finance managers, than one in medicine or pharmaceutical R&D. Pharmaceuticals. The data captured a 20-year period, from 1995 to 2014. Overall, it is a messy picture.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

OCTOBER 24, 2014

One of the biggest obstacles is that traditional functional departments often can’t meet the needs of IoT business models and have to evolve. Here are some of the challenges that I’ve observed: Product management. Weekly e-mails with detailed reports can also be set up, creating a comprehensive system of medication management.

Productivity 8

Productivity Products Company Engineering 8

Harvard Business Review

FEBRUARY 12, 2013

But the truth is that the really successful companies are highly focused, achieving unprecedented efficiencies by designing a business model with a razor-thin focus and learning to do the one thing really well. Does public ownership bring pressures to continually grow by going into new areas?

Succession 8

Succession Simon Airlines Business Model 8

Skip Prichard

JANUARY 14, 2021

“The biggest leadership challenge is to create the future while managing the present across the entire organization.” Platform businesses are a new economic model that replaces or augments the traditional value chain company that was the dominant model in the first, second and third industrial revolution.

Brand 96

Brand Insurance Participative Open-book 96

Harvard Business Review

JUNE 24, 2015

Managers and other business leaders face a dilemma: with increasingly diverse environments to manage and rising stakes to get it right, how do they identify the most effective approach to business strategy and marshal the right thinking and behaviors to conceive and execute it, supported by the appropriate frameworks and tools?

Strategy 8

Strategy Competitive Advantage Environment Execution 8

Harvard Business Review

JULY 25, 2012

To succeed, therefore, managers have to learn when and how to abandon the strategies they have grown up with. Its business model was looking out-dated as the Internet and mail order channels became more important. Pharmaceutical benefit managers (PBMs) were also growing in strength and aggressiveness.

Strategy 14

Strategy First-mover Advantage Pharmaceuticals Learning-by-Doing 14

Harvard Business Review

FEBRUARY 6, 2018

Consider its decision to pursue the market for pharmaceutical distribution, or the recent announcement that it will be teaming up with Berkshire Hathaway and JP Morgan Chase to create joint solutions for reducing the health care spending of more than 1 million employees and their families. Making routine transactions seamless and reliable.

Health Care 9

Health Care Retail Operations Insurance 9

Harvard Business Review

OCTOBER 26, 2017

Blockchain is a cryptographically secure, shared data layer that enterprises can use to digitally track the ownership of assets across trust boundaries, opening up new opportunities for cross-organizational collaboration and imaginative new business models. Powering the Supply Chain with Internet of Things (IoT) technology.

Supply Chain 8

Supply Chain Content Power Transportation 8

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. One antidote to these problems is to transform “access to medicine” from a relentless activist slogan to a fully-fledged business strategy. citizens than pharmaceuticals (the sector’s worst showing in 16 years).

Reputation 8

Reputation Pharmaceuticals Price Business Model 8

Harvard Business Review

JULY 20, 2017

This is the challenge for all kinds of disruptors, whether in the auto industry, pharmaceuticals, service industries, or healthcare. Scotiabank is also a leader in adopting this type of new model. The fact is, going it alone, we believe, is simply not the way to go at all. A portfolio approach can take many forms.

Innovation 11

Innovation Productivity Products Venture Capitalist 11

Harvard Business Review

MAY 25, 2017

More than 3,000 apps are now available to help manage diabetes alone. But traditional business models focused on and serving third-party reimbursement continue to struggle with how to monetize digital health tools. From 2015 to 2016, investors poured more than $8 billion into funding these tools.

Health Care 8

Health Care Trends Venture Funding Technology 8

Harvard Business Review

JULY 6, 2016

For 78-year-old Tony, 3,4 DAP — which can be obtained at low cost from compounding pharmacies or for free through a compassionate-use program supported by a small privately held company, Jacobus Pharmaceuticals — is a lifesaver. Pharmaceutical companies traditionally invest heavily in research and development.

Price 13

Price Pharmaceuticals Company Health Care 13